Drugs / Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection

Follow last change Apr 2025 re-read 3 minutes ago

Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection

Developed for: plasma cell myeloma
Investigated by: Bioray Laboratories · Shanghai Tongji Hospital, Tongji University School of Medicine

20262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
—	NCT07248176	Apr 2025 → Mar 2027 expected	plasma cell myeloma	Bioray Laboratories	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07248176 ↗
Modality	Cell therapy	“universal CAR-T cells targeting BCMA” NCT07248176 ↗
Route	Intravenous	“administered intravenously” NCT07248176 ↗